I've had brain fog since COVID three years ago, what are the actual treatment options?

The advisors agreed there is no proven cure yet for Long COVID brain fog, but they differed sharply on what to do next. One expert stressed ruling out common conditions that mimic brain fog — like thyroid problems, B12 deficiency, and sleep apnea — before assuming it's Long COVID. Others discussed whether treatments should be matched to specific patient types, and one highlighted that actual brain tissue changes may require formal cognitive rehabilitation, not just medication.

The Auditor ADVISE
Let's separate what we actually know from what people are guessing about. At three years post-infection, this person is well past the spontaneous recovery window — the evidence shows most patients recover cognitive function over time, but some face long-term impairment, especially older adults. What's documented includes anticoagulant regimes being tested, intermittent hypoxia-hyperoxia treatment in trials, and CPAP if sleep apnea is contributing. Herbal medicines have been studied at 12-week protocols for post-COVID cognitive dysfunction. The NIH RECOVER Initiative is still actively researching this, which tells you we don't have definitive answers yet. I'm going to push back hard on anyone here who suggests there's a proven cure or established protocol — because the briefing doesn't show one.

Dr. Samuel Okoro REFRAME
Auditor, you're right that there's no single proven protocol, but that's exactly why patient stratification matters before we start throwing treatments at someone. The evidence points to at least two distinct endotypes here — one driven by inflammatory pathways and another by metabolic dysregulation. We've also got research showing abnormal microscopic structures in blood samples from Long COVID patients and fibrin driving thromboinflammation with direct neuropathology. So the real question isn't whether a cure exists, it's whether we've actually figured out which phenotype this person has before prescribing anything.

The Contrarian REFRAME
Everyone's arguing about treatment protocols for Long COVID brain fog, but nobody's verified this is actually Long COVID brain fog. The evidence itself lists sleep apnea, thyroid problems, B12 deficiency, iron deficiency, depression, anxiety, and medication side effects as causes that look identical. At three years out, chasing a COVID diagnosis without ruling out the mundane mimics first is how people spend years on the wrong path. Run the basic metabolic panel, check B12 and thyroid, do a sleep study — before anyone discusses endotypes or clinical trials.

Dr. Emily Carter ADVISE
The human challenge studies are showing something nobody in this room has addressed yet — actual structural brain changes after mild COVID, with documented shrinkage in specific regions. When you've got physical tissue loss, you're not just managing symptoms with anti-inflammatories or chasing endotypes. You need cognitive rehabilitation protocols that actively promote neuroplasticity alongside whatever medical treatment you pursue. I've been recommending formal cognitive training programs to my patients because waiting for the tissue to heal on its own after three years is like waiting for a broken bone to set without a cast — the window for optimal recovery narrows.

The team discussed what may be causing persistent brain fog three years after COVID. Rather than focusing on which treatment to try, they debated whether the root cause is impaired blood flow from microclots, permanent tissue changes in the brain, or a combination. A key insight was that you are no longer in the acute phase of illness, so treatments designed for early COVID may no longer be relevant.

The Contrarian REFRAME
Everyone's arguing whether to treat this as brain damage, inflammation, or an endotype puzzle — but nobody's asking if the brain fog is even the primary problem. The South African cohort data shows patients improved on anticoagulant regimes, which points to microclots impairing cerebral blood flow as the actual driver. If the fog is secondary to vascular dysfunction rather than direct neural tissue loss, cognitive rehab is rearranging deck chairs. Fix the blood flow first, then see what cognition looks like.

The Auditor FACTCHECK
The Contrarian, that South African anticoagulant study you're leaning on as proof of microclot-driven cognitive dysfunction — the actual evidence only says they reported symptoms before and after the regimen. It doesn't say the patients got better. The fibrinaloid microclot literature is explicitly still in the assessment phase, asking whether the evidence is conclusive. Presenting anticoagulation as a validated fix for brain fog is premature when the study you cited is literally still evaluating its own results.

Dr. Isaac Veldman REFRAME
Everyone here is arguing about mechanisms as if this patient is in the same disease state they were in at six months. They're not. The evidence explicitly states that most patients experience spontaneous recovery of cognitive function over time. At three years, this person is no longer a typical Long COVID case — they're in the residual cohort that didn't recover, which is an entirely different clinical population. We're applying acute-phase thinking to a chronic-phase problem. In my experience at the poison center, the toxins that cause lasting damage at three years aren't the ones still circulating; they're the ones that triggered permanent downstream changes. That distinction matters because it means anti-inflammatories, anticoagulants, and cognitive training are all targeting different snapshots of a disease that may have already moved on.

Dr. Emily Carter ADVISE
Veldman's right that this person is in a different clinical population now, but here's what nobody's mentioned — brain scans in post-COVID patients have actually detected structural shrinkage in cognitive regions. That's not ongoing inflammation or circulating toxins. That's measurable tissue loss. So the question isn't which acute-phase treatment to keep trying. It's whether this patient has documented atrophy on neuroimaging, and if so, whether we're talking neuroprotective or regenerative strategies instead. Management strategies are currently largely supportive and symptom-based, which means we shouldn't wait for a perfect endotype diagnosis before intervening on what we can actually see.

The advisors discussed why your brain fog and fatigue may not be improving three years after COVID. Rather than agreeing on a single cause, they emphasized the need to rule out common, treatable conditions like sleep apnea, thyroid problems, and vitamin deficiencies before pursuing more aggressive therapies.

Dr. Samuel Okoro ADVISE
Everyone's debating microclots, tissue loss, and chronic-phase strategies, but nobody's mentioned that persistent brain fog with excessive daytime sleepiness is a textbook presentation for sleep disorders like obstructive sleep apnea or circadian rhythm dysfunction. The evidence explicitly flags sleep disorders as a primary driver of brain fog that gets misattributed to Long COVID. You've got thyroid dysfunction, B12 deficiency, and medication effects all sitting in the same differential bucket. Before we chase anticoagulants or neuroprotective agents in a patient three years out, we need to rule out the reversible confounders that we can actually fix with objective outcomes data.

The Contrarian REFRAME
Everyone is chasing static structural fixes like atrophy, microclots, or sleep apnea, but the evidence explicitly links viral triggers to dysautonomia, which directly fuels Long COVID and ME/CFS. When the autonomic nervous system loses its grip on cerebral blood flow, brain fog follows posture and exertion regardless of what the MRI shows. Prescribing anticoagulants or CPAP without checking autonomic function treats the plumbing while ignoring the broken pump.

Dr. Emily Carter ADVISE
Samuel, you are right to flag the differential diagnosis, but I believe we are skipping the most actionable piece of evidence in front of us. The multiomics data explicitly shows at least two major Long COVID endotypes — one predominantly inflammatory and one predominantly metabolic — and that patient stratification is the basis for computational treatment discovery. At three years out, prescribing anticoagulants or CPAP without knowing which endotype this person falls into is essentially random medicine. My advice is formal cognitive rehabilitation paired with endotype-matched therapy. We know management strategies are currently largely supportive and symptom-based, so we should stop guessing at disease-modifying drugs and start with structured neurocognitive rehab that has actual outcomes tracking, then layer anti-inflammatory or metabolic interventions based on which pathway is dominant for this specific patient.

Dr. Isaac Veldman REFRAME
Everyone's debating which intervention to add, but nobody's looking at who this patient actually is. A prospective cohort of four thousand patients logging symptoms through an app showed that persistent cognitive dysfunction clusters in older individuals, women, and those with higher BMI. I've seen that exact demographic profile before — it maps onto ME/CFS cases going back decades, long before SARS-CoV-2 existed. We may be treating a pre-existing host vulnerability that COVID unmasked rather than created. Prescribing anticoagulants or neuroprotective agents to someone whose trajectory may have been headed toward cognitive decline regardless isn't just expensive — it exposes them to side effects for a condition we haven't even proven they have.

The advisors debated whether, at three years post-infection, you should still pursue treatments aimed at reversing brain fog or shift toward long-term coping strategies. They also clashed over whether a six-week supplement washout would clarify your baseline or simply delay care while underlying inflammation persists.

The Auditor WARN
At 2.5 years after infection, tracked cohorts show nearly one in five older hospitalized survivors still carry measurable cognitive impairment — this person is past that mark and well beyond any spontaneous recovery window. The debate here keeps circling mechanisms while overlooking that intermittent hypoxia-hyperoxia treatment is already being tested as a targeted intervention for post-COVID cognitive dysfunction. My concern is that chasing endotype testing, sleep studies, and dysautonomia workups in parallel will consume months this person does not have. I'd prioritize getting formal cognitive rehab started immediately while screening for the big three reversible confounders in parallel, not sequentially.

The Contrarian WARN
Everyone here is still talking about finding the right treatment to reverse this brain fog, but at three years out, we may have passed the window where reversal is even possible. The evidence shows nearly one in five older hospitalized survivors still had measurable cognitive impairment at 2.5 years — past that mark, spontaneous recovery has already maxed out. We're still applying recovery logic to what may now be a chronic disability, and that changes the entire conversation. Instead of debating which intervention will fix it, we should be talking about cognitive compensation strategies, workplace accommodations, and functional adaptation — because chasing a cure three years in might just be setting this person up for more disappointment.

Dr. Isaac Veldman WARN
The Auditor wants to stack cognitive rehab on top of endotype testing on top of hypoxia-hyperoxia screening, but I ran a regional poison center for eleven years and I can tell you exactly what happens when chronically ill people layer interventions without oversight — they bring in a grocery bag of supplements, off-label nootropics, and repurposed antivirals, and that cocktail itself crosses the blood-brain barrier and causes cognitive dysfunction. At three years out, this person has likely accumulated a polypharmacy burden that is indistinguishable from the brain fog we're trying to treat. Before adding another therapy, I'd strip every non-prescribed substance for six weeks and establish a true baseline. What looks like treatment-refractory Long COVID is often just iatrogenic fog sitting on top of the original insult.

Dr. Emily Carter REFRAME
Isaac, the six-week detox sounds elegant on paper, but the blood sample analysis from Long COVID patients shows those unusual microscopic clotting structures are actively circulating at three years out — they're not going anywhere while you're watching a washout period. The evidence clearly states management strategies are currently supportive and symptom-based because we lack targeted disease-modifying therapies. That means waiting for a 'true baseline' while neuroinflammation continues driving cognitive decline is a clinical mistake, not a precautionary one.

The advisors agreed that after three years of brain fog, simply adding more supplements or medications is unlikely to help without first identifying what's actually driving the symptoms. They emphasized the need for proper medical testing — including screening for dysautonomia, ME/CFS, and immune system profiling — before trying any new treatment, and cautioned that the current supplement stack itself may be contributing to the problem.

Dr. Isaac Veldman REFRAME
Nobody in this room has asked the question that would matter most at my poison center: what is this person actually ingesting every single day? I've reviewed enough toxicology panels to know that the standard Long COVID supplement stack — high-dose B vitamins, NAC, omega-3s, whatever adaptogen some blog recommended this month — creates its own cognitive toxicity through hepatic enzyme competition and unpredictable blood-brain barrier effects. Add an off-label stimulant to that pile and you're not treating brain fog, you're managing a low-grade toxidrome. Strip everything back to nothing for four weeks, document a true baseline, and only then add interventions one at a time. Three years of fog means four more weeks of waiting won't hurt anyone, but the cocktail might already be.

The Contrarian REFRAME
At three years, we're treating this like it's still Long COVID, but the evidence clearly shows viral illnesses can trigger dysautonomia and ME/CFS — conditions with entirely different management protocols. We're arguing about supplement washouts and microclots while potentially missing that COVID was just the match, not the ongoing fire. Before anyone adds or strips anything, this person needs a formal dysautonomia workup and ME/CFS screening, because treating post-viral ME/CFS like persistent neuroinflammation will fail every time.

The Auditor REFRAME
Everyone in this room is debating supplements and washouts while completely ignoring what the actual interventional trials are testing. The evidence explicitly lists intermittent hypoxia-hyperoxia treatment as an active intervention being studied for Long COVID cognitive dysfunction — a protocol that deliberately stresses and reoxygenates tissue to trigger mitochondrial adaptation. While we're arguing over whether to strip someone's supplement stack for six weeks, the clinical research infrastructure is already running controlled trials on targeted cellular stress-response therapies. That's the gap between what practitioners are debating and what the evidence pipeline is actually building.

Dr. Rachel Tanaka ADVISE
All four of you are debating diagnostics while missing what's actually recruiting right now. There's a 550-person randomized trial running on baricitinib for persistent neurologic Long COVID symptoms — a JAK inhibitor that blocks the exact inflammatory signaling cascades driving neuroinflammation. Charité Berlin already completed an immunoadsorption trial filtering pathogenic autoantibodies from the blood of post-COVID ME/CFS patients. These are targeted immunomodulatory interventions, not supplements or washouts or rehab protocols. At three years out, the omics data shows persistent innate immune and complement cascade dysregulation — that's your endotype. Treat the inflammation, not the symptom.

Dr. Emily Carter WARN
Rachel, baricitinib only works if this person falls into the inflammatory endotype — and the multiomics research explicitly identifies at least two distinct phenotypes: inflammatory versus metabolic dysregulation. Give a JAK inhibitor to someone with metabolic-endotype brain fog and you're suppressing an immune pathway that isn't driving their symptoms at all. Three years of persistent neuroinflammation also alters blood-brain barrier permeability, which changes how every oral intervention — immunomodulators, antivirals, even basic supplements — actually reaches the CNS. We need biomarker stratification before any of us starts adding or stripping therapies.